Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs

Abstract excerpt

(anaplastic lymphoma kinase) fusion gene in non-small-cell lung cancer (NSCLC) was first identified in 2007. As the EML4-ALK fusion protein promotes carcinogenesis in lung cells, much attention has been paid to it, leading to the development of therapies for patients with NSCLC. These therapies include ALK tyrosine kinase inhibitors and heat shock protein 90 inhibitors. However, detailed information on the entire...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations
• Share to Peptidase Inhibition and Analysis